{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:43:57Z","timestamp":1787024637658,"version":"build-2736575974"},"reference-count":181,"publisher":"Bentham Science Publishers Ltd.","issue":"29","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,9,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Biliary Tract Cancers (BTC) are rare malignancies with a poor prognosis.\nThere are many challenges encountered in treating these patients in daily practice as well as in clinical,\ntranslational and basic research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This review summarises the most relevant challenges in clinical and translational research in\nBTCs and suggests potential solutions towards an improvement in quality of life and outcomes of patients\ndiagnosed with such malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>The main challenge is the low number of patients with BTCs, complicated by the aggressive\nnatural behaviour of cancer and the lack of funding sources for research. In addition, the clinical characteristics\nof these patients and the specific cancer-related complications challenge clinical research and\nclinical trial recruitment. It is worth highlighting that BTCs are a group of different malignancies (cholangiocarcinoma,\ngallbladder cancer and ampullary cancer) rather than a unique homogeneous disease.\nThese subgroups differ not only in molecular aspects, but also in clinical and demographic characteristics.\nIn addition, tailored imaging and quality of life assessment are required to tackle some of the issues\nspecific to BTCs. Finally, difficulties in tissue acquisition both in terms of biopsy size and inclusion\nof sufficient tumour within the samples, may adversely impact translational and basic research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Increasing awareness among patients and clinicians regarding BTC and the need for further\nresearch and treatment development may address some of the main challenges in BTC research.\nInternational collaboration is mandatory to progress the field.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0929867327666200123090153","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T08:30:48Z","timestamp":1579768248000},"page":"4756-4777","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Clinical and Translational Research Challenges in Biliary Tract Cancers"],"prefix":"10.2174","volume":"27","author":[{"given":"Angela","family":"Lamarca","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Frizziero","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mair\u00e9ad G.","family":"McNamara","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/cncr.10831","volume":"95","author":"Takada T.","year":"2002","unstructured":"Takada T.; Amano H.; Yasuda H.; Nimura Y.; Matsushiro T.; Kato H.; Nagakawa T.; Nakayama T.; Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002,95(8),1685-1695","journal-title":"Cancer"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","volume":"27","author":"Valle J.W.","year":"2016","unstructured":"Valle J.W.; Borbath I.; Khan S.A.; Huguet F.; Gruenberger T.; Arnold D.; Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol ESMO Guidelines Committee2016,27(Suppl. 5),v28-v37","journal-title":"Ann Oncol"},{"key":"ref=3","author":"Amin M.B.","unstructured":"Amin M.B.; Edge S.; Greene F.; Byrd D.R.; Brookland R.K.; Washington M.K.; Gershenwald J.E.; Compton C.C.; Hess K.R.; Sullivan D.C.; Jessup J.M.; Brierley J.D.; Gaspar L.E.; Schilsky R.L.; Balch C.M.; Winchester D.P.; Asare E.A.; Madera M.; Gress D.M.; Meyer L.R.;  (Eds.). AJCC Cancer Staging Manual; Springer-Verlag:\nNew York., 2010. Ref Type: Edited Book."},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.24351","volume":"54","author":"Tyson G.L.","year":"2011","unstructured":"Tyson G.L.; El-Serag H.B.; Risk factors for cholangiocarcinoma. Hepatology 2011,54(1),173-184","journal-title":"Hepatology"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/jnci\/89.15.1132","volume":"89","author":"Zatonski W.A.","year":"1997","unstructured":"Zatonski W.A.; Lowenfels A.B.; Boyle P.; Maisonneuve P.; Bueno de Mesquita H.B.; Ghadirian P.; Jain M.; Przewozniak K.; Baghurst P.; Moerman C.J.; Simard A.; Howe G.R.; McMichael A.J.; Hsieh C.C.; Walker A.M.; Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer. J Natl Cancer Inst 1997,89(15),1132-1138","journal-title":"J Natl Cancer Inst"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/annonc\/10.suppl_4.S308","volume":"10","author":"Chapman R.W.","year":"1999","unstructured":"Chapman R.W.; Risk factors for biliary tract carcinogenesis. Ann Oncol 1999,10(Suppl. 4),308-311","journal-title":"Ann Oncol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"Banales J.M.","year":"2016","unstructured":"Banales J.M.; Cardinale V.; Carpino G.; Marzioni M.; Andersen J.B.; Invernizzi P.; Lind G.E.; Folseraas T.; Forbes S.J.; Fouassier L.; Geier A.; Calvisi D.F.; Mertens J.C.; Trauner M.; Benedetti A.; Maroni L.; Vaquero J.; Macias R.I.; Raggi C.; Perugorria M.J.; Gaudio E.; Boberg K.M.; Marin J.J.; Alvaro D.; Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016,13(5),261-280","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.2012.41.5984","volume":"20","author":"Wang Y.","year":"2013","unstructured":"Wang Y.; Li J.; Xia Y.; Gong R.; Wang K.; Yan Z.; Wan X.; Liu G.; Wu D.; Shi L.; Lau W.; Wu M.; Shen F.; Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol 2013,20(31),1188-1195","journal-title":"J Clin Oncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1200\/JCO.2010.33.8020","volume":"29","author":"Wang S.J.","year":"2011","unstructured":"Wang S.J.; Lemieux A.; Kalpathy-Cramer J.; Ord C.B.; Walker G.V.; Fuller C.D.; Kim J.S.; Thomas C.R.; Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol 2011,29(35),4627-4632","journal-title":"J Clin Oncol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/annonc\/mdv483","volume":"27","author":"Bridgewater J.","year":"2016","unstructured":"Bridgewater J.; Lopes A.; Wasan H.; Malka D.; Jensen L.; Okusaka T.; Knox J.; Wagner D.; Cunningham D.; Shannon J.; Goldstein D.; Moehler M.; Bekaii-Saab T.; McNamara M.G.; Valle J.W.; Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol 2016,27(1),134-140","journal-title":"Ann Oncol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/00000658-200203000-00011","volume":"235","author":"Weber S.M.","year":"2002","unstructured":"Weber S.M.; DeMatteo R.P.; Fong Y.; Blumgart L.H.; Jarnagin W.R.; Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann Surg 2002,235(3),392-399","journal-title":"Ann Surg"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/00000658-199801000-00011","volume":"227","author":"Madariaga J.R.","year":"1998","unstructured":"Madariaga J.R.; Iwatsuki S.; Todo S.; Lee R.G.; Irish W.; Starzl T.E.; Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg 1998,227(1),70-79","journal-title":"Ann Surg"},{"key":"ref=13","first-page":"311","volume":"49","author":"Hanazaki K.","year":"2002","unstructured":"Hanazaki K.; Kajikawa S.; Shimozawa N.; Shimada K.; Hiraguri M.; Koide N.; Adachi W.; Amano J.; Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis. Hepatogastroenterology 2002,49(44),311-316","journal-title":"Hepatogastroenterology"},{"key":"ref=14","first-page":"1116","volume":"49","author":"Tanaka S.","year":"2002","unstructured":"Tanaka S.; Hirohashi K.; Tanaka H.; Yamamoto T.; Kubo S.; Shuto T.; Takemura S.; Kinoshita H.; Prognostic factors in patients with carcinoma of the papilla of Vater. Hepatogastroenterology 2002,49(46),1116-1119","journal-title":"Hepatogastroenterology"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00535-006-1877-z","volume":"41","author":"Miwa S.","year":"2006","unstructured":"Miwa S.; Miyagawa S.; Kobayashi A.; Akahane Y.; Nakata T.; Mihara M.; Kusama K.; Soeda J.; Ogawa S.; Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol 2006,41(9),893-900","journal-title":"J Gastroenterol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s00268-005-7763-7","volume":"29","author":"Jan Y.Y.","year":"2005","unstructured":"Jan Y.Y.; Yeh C.N.; Yeh T.S.; Hwang T.L.; Chen M.F.; Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma. World J Surg 2005,29(7),894-898","journal-title":"World J Surg"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.gassur.2005.08.034","volume":"9","author":"Riall T.S.","year":"2005","unstructured":"Riall T.S.; Cameron J.L.; Lillemoe K.D.; Campbell K.A.; Sauter P.K.; Coleman J.; Abrams R.A.; Laheru D.; Hruban R.H.; Yeo C.J.; Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survival. J Gastrointest Surg 2005,9(9),1191-1204","journal-title":"J Gastrointest Surg"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/(SICI)1096-9098(199703)64:3< 242:AID-JSO12>3.0.CO;2-6","volume":"64","author":"Wade T.P.","year":"1997","unstructured":"Wade T.P.; Prasad C.N.; Virgo K.S.; Johnson F.E.; Experience with distal bile duct cancers in U.S. Veterans Affairs hospitals: 1987-1991. J Surg Oncol 1997,64(3),242-245","journal-title":"J Surg Oncol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.13032\/tjop.2052-5931.100109","volume":"2","author":"Lamarca A.","year":"2014","unstructured":"Lamarca A.; Should patients with resected bile duct cancer\nreceive an adjuvant treatment? J Oncopathol (12).2014,2(4),57-68","journal-title":"J Oncopathol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","volume":"30","author":"Horgan A.M.","year":"2012","unstructured":"Horgan A.M.; Amir E.; Walter T.; Knox J.J.; Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012,30(16),1934-1940","journal-title":"J Clin Oncol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2012.7352","volume":"308","author":"Neoptolemos J.P.","year":"2012","unstructured":"Neoptolemos J.P.; Moore M.J.; Cox T.F.; Valle J.W.; Palmer D.H.; McDonald A.C.; Carter R.; Tebbutt N.C.; Dervenis C.; Smith D.; Glimelius B.; Charnley R.M.; Lacaine F.; Scarfe A.G.; Middleton M.R.; Anthoney A.; Ghaneh P.; Halloran C.M.; Lerch M.M.; Ol\u00e1h A.; Rawcliffe C.L.; Verbeke C.S.; Campbell F.; B\u00fcchler M.W.; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012,308(2),147-156","journal-title":"JAMA"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1200\/JCO.2012.44.1634","volume":"30","author":"Bariani G.M.","year":"2012","unstructured":"Bariani G.M.; Braghiroli M.I.; Riechelmann R.P.; Poor evidence to standardize adjuvant treatment for patients with biliary tract cancer. J Clin Oncol 2012,30(33),4173","journal-title":"J Clin Oncol"},{"key":"ref=23","volume":"35","year":"2017","unstructured":"emox versus surveillance following surgery of localized\nbiliary tract cancer: Results of the PRODIGE 12-\nACCORD 18 (UNICANCER GI) phase III trial. J Clin\nOncol Julien Edeline, Franck Bonnetain, Jean Marc Phelip, J\u00e9r\u00f4me Watelet, Pascal Hammel, Jean-Paul Joly, Meher Ben Abdelghani, Olivier Rosmorduc, Karine Bouhier-Leporrier, Jean- Louis Jouve, Roger Faroux, V\u00e9ronique Guerin Meyer, Eric Assenat, Jean Francois Seitz, David Malka, Christophe Louvet, Aurelie Bertaut, Beata Juzyna, Trevor Stanbury, Eveline Boucher2017,35(suppl 4S; abstract 225)","journal-title":"J Clin\nOncol"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","volume":"20","author":"Ben-Josef E.","year":"2015","unstructured":"Ben-Josef E.; Guthrie K.A.; El-Khoueiry A.B.; SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol 2015,20(33),2617-2622","journal-title":"J Clin Oncol"},{"key":"ref=25","volume":"35","year":"2017","unstructured":"Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. J Clin Oncol John Neil Primrose, Richard Fox, Daniel H. Palmer, Raj Prasad, Darius Mirza, David Alan Anthoney, Philippa Corrie, Stephen Falk, Harpreet Singh Wasan, Paul J. Ross, Lucy R. Wall, Jonathan Wadsley, T.R. Jeffry Evans, Deborah Stocken, Raaj Praseedom, David Cunningham, O James Garden, Clive Stubbs, Juan W. Valle, John A. Bridgewater2017,35(15 Suppl)","journal-title":"J Clin Oncol"},{"key":"ref=26","unstructured":"ClinicalTrialsgov ClinicalTrials.gov [December 2019];2020","journal-title":"ClinicalTrialsgov"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s00268-012-1638-5","volume":"36","author":"Ruys A.T.","year":"2012","unstructured":"Ruys A.T.; van Haelst S.; Busch O.R.; Rauws E.A.; Gouma D.J.; van Gulik T.M.; Long-term survival in hilar cholangiocarcinoma also possible in unresectable patients. World J Surg 2012,36(9),2179-2186","journal-title":"World J Surg"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000011961","volume":"56","author":"Raderer M.","year":"1999","unstructured":"Raderer M.; Hejna M.H.; Valencak J.B.; Kornek G.V.; Weinl\u00e4nder G.S.; Bareck E.; Lenauer J.; Brodowicz T.; Lang F.; Scheithauer W.; Two consecutive phase II studies of 5-fluorouracil\/leucovorin\/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 1999,56(3),177-180","journal-title":"Oncology"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"Okusaka T.","year":"2010","unstructured":"Okusaka T.; Nakachi K.; Fukutomi A.; Mizuno N.; Ohkawa S.; Funakoshi A.; Nagino M.; Kondo S.; Nagaoka S.; Funai J.; Koshiji M.; Nambu Y.; Furuse J.; Miyazaki M.; Nimura Y.; Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010,103(4),469-474","journal-title":"Br J Cancer"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2015.61.3778","volume":"20","author":"Tao R.","year":"2016","unstructured":"Tao R.; Krishnan S.; Bhosale, PR Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol 2016,20(34),219-226","journal-title":"J Clin Oncol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejso.2014.09.007","volume":"41","author":"Al-Adra D.P.","year":"2015","unstructured":"Al-Adra D.P.; Gill R.S.; Axford S.J.; Shi X.; Kneteman N.; Liau S.S.; Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol 2015,41(1),120-127","journal-title":"Eur J Surg Oncol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/RLU.0000000000000904","volume":"40","author":"Edeline J.","year":"2015","unstructured":"Edeline J.; Du F.L.; Rayar M.; Rolland Y.; Beuzit L.; Boudjema K.; Rohou T.; Latournerie M.; Campillo-Gimenez B.; Garin E.; Boucher E.; Glass Microspheres 90Y Selective Internal Radiation Therapy and Chemotherapy as First-Line Treatment of Intrahepatic Cholangiocarcinoma. Clin Nucl Med 2015,40(11),851-855","journal-title":"Clin Nucl Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","volume":"96","author":"Eckel F.","year":"2007","unstructured":"Eckel F.; Schmid R.M.; Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007,96(6),896-902","journal-title":"Br J Cancer"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1023\/B:DRUG.0000011797.09549.53","volume":"22","author":"Tsavaris N.","year":"2004","unstructured":"Tsavaris N.; Kosmas C.; Gouveris P.; Gennatas K.; Polyzos A.; Mouratidou D.; Tsipras H.; Margaris H.; Papastratis G.; Tzima E.; Papadoniou N.; Karatzas G.; Papalambros E.; Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 2004,22(2),193-198","journal-title":"Invest New Drugs"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","volume":"7","author":"Glimelius B.","year":"1996","unstructured":"Glimelius B.; Hoffman K.; Sj\u00f6d\u00e9n P.O.; Jacobsson G.; Sellstr\u00f6m H.; Enander L.K.; Linn\u00e9 T.; Svensson C.; Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996,7(6),593-600","journal-title":"Ann Oncol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"Valle J.","year":"2010","unstructured":"Valle J.; Wasan H.; Palmer D.H.; Cunningham D.; Anthoney A.; Maraveyas A.; Madhusudan S.; Iveson T.; Hughes S.; Pereira S.P.; Roughton M.; Bridgewater J.; Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med ABC-02 Trial Investigators2010,362(14),1273-1281","journal-title":"N Engl J Med"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.ejca.2015.05.018","volume":"51","author":"Lamarca A.","year":"2015","unstructured":"Lamarca A.; Benafif S.; Ross P.; Bridgewater J.; Valle J.W.; Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. Eur J Cancer 2015,51(13),1694-1703","journal-title":"Eur J Cancer"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.ejca.2012.11.024","volume":"49","author":"Bridgewater J.","year":"2013","unstructured":"Bridgewater J.; Palmer D.; Cunningham D.; Iveson T.; Gillmore R.; Waters J.; Harrison M.; Wasan H.; Corrie P.; Valle J.; Outcome of second-line chemotherapy for biliary tract cancer. Eur J Cancer 2013,49(6),1511","journal-title":"Eur J Cancer"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","volume":"25","author":"Lamarca A.","year":"2014","unstructured":"Lamarca A.; Hubner R.A.; David Ryder W.; Valle J.W.; Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 2014,25(12),2328-2338","journal-title":"Ann Oncol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ejca.2012.08.003","volume":"49","author":"Walter T.","year":"2013","unstructured":"Walter T.; Horgan A.M.; McNamara M.; McKeever L.; Min T.; Hedley D.; Serra S.; Krzyzanowska M.K.; Chen E.; Mackay H.; Feld R.; Moore M.; Knox J.J.; Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer 2013,49(2),329-335","journal-title":"Eur J Cancer"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1007\/s10637-010-9417-3","volume":"29","author":"Oh S.Y.","year":"2011","unstructured":"Oh S.Y.; Jeong C.Y.; Hong S.C.; Kim T.H.; Ha C.Y.; Kim H.J.; Lee G.W.; Hwang I.G.; Jang J.S.; Kwon H.C.; Kang J.H.; Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs 2011,29(5),1066-1072","journal-title":"Invest New Drugs"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/COC.0b013e31818c08ff","volume":"32","author":"Lee S.","year":"2009","unstructured":"Lee S.; Oh S.Y.; Kim B.G.; Kwon H.C.; Kim S.H.; Rho M.H.; Kim Y.H.; Rho M.S.; Jeong J.S.; Kim H.J.; Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. Am J Clin Oncol 2009,32(4),348-352","journal-title":"Am J Clin Oncol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s10637-010-9553-9","volume":"30","author":"Sasaki T.","year":"2012","unstructured":"Sasaki T.; Isayama H.; Nakai Y.; Mizuno S.; Yamamoto K.; Yagioka H.; Yashima Y.; Kawakubo K.; Kogure H.; Togawa O.; Matsubara S.; Ito Y.; Sasahira N.; Hirano K.; Tsujino T.; Toda N.; Tada M.; Omata M.; Koike K.; Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 2012,30(2),708-713","journal-title":"Invest New Drugs"},{"key":"ref=44","volume":"37","year":"2019","unstructured":"ABC-06 | A randomised\nphase III, multi-centre, open-label study of Active\nSymptom Control (ASC) alone or ASC with oxaliplatin \/ 5-\nFU chemotherapy (ASC+mFOLFOX) for patients (pts) with\nlocally advanced \/ metastatic biliary tract cancers (ABC)\npreviously-treated with cisplatin\/gemcitabine (CisGem)\nchemotherapy. J Clin Oncol Angela Lamarca DPHSWPRYTMAAea2019,37(suppl; abstr 4003)","journal-title":"J Clin Oncol"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1200\/JCO.2010.28.4075","volume":"20","author":"Lubner S.J.","year":"2010","unstructured":"Lubner S.J.; Mahoney M.R.; Kolesar J.L.; Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 2010,20(28),3491-3497","journal-title":"J Clin Oncol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","volume":"16","author":"Valle J.W.","year":"2015","unstructured":"Valle J.W.; Wasan H.; Lopes A.; Backen A.C.; Palmer D.H.; Morris K.; Duggan M.; Cunningham D.; Anthoney D.A.; Corrie P.; Madhusudan S.; Maraveyas A.; Ross P.J.; Waters J.S.; Steward W.P.; Rees C.; Beare S.; Dive C.; Bridgewater J.A.; Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol 2015,16(8),967-978","journal-title":"Lancet Oncol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/bjc.2013.432","volume":"20","author":"Lee J.K.","year":"2013","unstructured":"Lee J.K.; Capanu M.; O\u2019Reilly E.M.; A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. Br J Cancer 2013,20(109),915-919","journal-title":"Br J Cancer"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","volume":"15","author":"Malka D.","year":"2014","unstructured":"Malka D.; Cervera P.; Foulon S.; Trarbach T.; de la Fouchardi\u00e8re C.; Boucher E.; Fartoux L.; Faivre S.; Blanc J.F.; Viret F.; Assenat E.; Seufferlein T.; Herrmann T.; Grenier J.; Hammel P.; Dollinger M.; Andr\u00e9 T.; Hahn P.; Heinemann V.; Rousseau V.; Ducreux M.; Pignon J.P.; Wendum D.; Rosmorduc O.; Greten T.F.; Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol BINGO investigators2014,15(8),819-828","journal-title":"Lancet Oncol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","volume":"7","author":"Valle J.W.","year":"2017","unstructured":"Valle J.W.; Lamarca A.; Goyal L.; Barriuso J.; Zhu A.X.; New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov 2017,7(9),943-962","journal-title":"Cancer Discov"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"v851-v934","DOI":"10.1093\/annonc\/mdz394","volume":"30","year":"2019","unstructured":"ClarIDHy: A global,\nphase 3, randomized, double-blind study of ivosidenib\n(IVO) vs placebo in patients with advanced cholangiocarcinoma\n(CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Annals of Oncology G.K.Abou-Alfa TMMMJRKKSLea2019,30(suppl_5),v851-v934","journal-title":"Annals of Oncology"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","volume":"20","author":"Javle M.","year":"2018","unstructured":"Javle M.; Lowery M.; Shroff R.T.; Phase I.I.; Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol 2018,20(36),276-282","journal-title":"J Clin Oncol"},{"key":"ref=52","unstructured":"PubMed PubMed [December 2019];2020 []","journal-title":"PubMed PubMed"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","volume":"33","author":"Patel T.","year":"2001","unstructured":"Patel T.; Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001,33(6),1353-1357","journal-title":"Hepatology"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/annonc\/mds652","volume":"24","author":"Bertuccio P.","year":"2013","unstructured":"Bertuccio P.; Bosetti C.; Levi F.; Decarli A.; Negri E.; La Vecchia C.; A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol 2013,24(6),1667-1674","journal-title":"Ann Oncol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"Siegel R.L.","year":"2016","unstructured":"Siegel R.L.; Miller K.D.; Jemal A.; Cancer statistics, 2016. CA Cancer J Clin 2016,66(1),7-30","journal-title":"CA Cancer J Clin"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1158\/1055-9965.EPI-05-0811","volume":"15","author":"McGlynn K.A.","year":"2006","unstructured":"McGlynn K.A.; Tarone R.E.; El-Serag H.B.; A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006,15(6),1198-1203","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/canjclin.50.1.7","volume":"50","author":"Greenlee R.T.","year":"2000","unstructured":"Greenlee R.T.; Murray T.; Bolden S.; Wingo P.A.; Cancer statistics, 2000. CA Cancer J Clin 2000,50(1),7-33","journal-title":"CA Cancer J Clin"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/canjclin.53.1.5","volume":"53","author":"Jemal A.","year":"2003","unstructured":"Jemal A.; Murray T.; Samuels A.; Ghafoor A.; Ward E.; Thun M.; J. Cancer statistics, 2003. CA Cancer J Clin 2003,53(1),5-26","journal-title":"CA Cancer J Clin"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","volume":"55","author":"Jemal A.","year":"2005","unstructured":"Jemal A.; Murray T.; Ward E.; Samuels A.; Tiwari R.C.; Ghafoor A.; Feuer E.J.; Thun M.; J. Cancer statistics, 2005. CA Cancer J Clin 2005,55(1),10-30","journal-title":"CA Cancer J Clin"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"56","author":"Jemal A.","year":"2006","unstructured":"Jemal A.; Siegel R.; Ward E.; Murray T.; Xu J.; Smigal C.; Thun M.; J. Cancer statistics, 2006. CA Cancer J Clin 2006,56(2),106-130","journal-title":"CA Cancer J Clin"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"Jemal A.","year":"2007","unstructured":"Jemal A.; Siegel R.; Ward E.; Murray T.; Xu J.; Thun M.; J. Cancer statistics, 2007. CA Cancer J Clin 2007,57(1),43-66","journal-title":"CA Cancer J Clin"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"Jemal A.","year":"2009","unstructured":"Jemal A.; Siegel R.; Ward E.; Hao Y.; Xu J.; Thun M.; J. Cancer statistics, 2009. CA Cancer J Clin 2009,59(4),225-249","journal-title":"CA Cancer J Clin"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"Jemal A.","year":"2010","unstructured":"Jemal A.; Siegel R.; Xu J.; Ward E.; Cancer statistics, 2010. CA Cancer J Clin 2010,60(5),277-300","journal-title":"CA Cancer J Clin"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"Siegel R.","year":"2013","unstructured":"Siegel R.; Naishadham D.; Jemal A.; Cancer statistics, 2013. CA Cancer J Clin 2013,63(1),11-30","journal-title":"CA Cancer J Clin"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"Siegel R.","year":"2014","unstructured":"Siegel R.; Ma J.; Zou Z.; Jemal A.; Cancer statistics, 2014. CA Cancer J Clin 2014,64(1),9-29","journal-title":"CA Cancer J Clin"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"Siegel R.L.","year":"2015","unstructured":"Siegel R.L.; Miller K.D.; Jemal A.; Cancer statistics, 2015. CA Cancer J Clin 2015,65(1),5-29","journal-title":"CA Cancer J Clin"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"Siegel R.L.","year":"2017","unstructured":"Siegel R.L.; Miller K.D.; Jemal A.; Cancer Statistics, 2017. CA Cancer J Clin 2017,67(1),7-30","journal-title":"CA Cancer J Clin"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1093\/annonc\/mdt301","volume":"24","author":"Bosetti C.","year":"2013","unstructured":"Bosetti C.; Bertuccio P.; Malvezzi M.; Levi F.; Chatenoud L.; Negri E.; La Vecchia C.; Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Ann Oncol 2013,24(10),2657-2671","journal-title":"Ann Oncol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","volume":"47","author":"Gatta G.","year":"2011","unstructured":"Gatta G.; van der Zwan J.M.; Casali P.G.; Siesling S.; Dei Tos A.P.; Kunkler I.; Otter R.; Licitra L.; Mallone S.; Tavilla A.; Trama A.; Capocaccia R.; RARECARE working group. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011,47(17),2493-2511","journal-title":"Eur J Cancer"},{"key":"ref=70","unstructured":"Cancer52 Cancer52 [December 2019).];","journal-title":"Cancer52 Cancer52"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S1470-2045(12)70570-3","volume":"14","author":"Keat N.","year":"2013","unstructured":"Keat N.; Law K.; Seymour M.; Welch J.; Trimble T.; Lascombe D.; Negrouk A.; International rare cancers initiative. Lancet Oncol 2013,14(2),109-110","journal-title":"Lancet Oncol"},{"key":"ref=72","year":"2020","unstructured":"Alan Morement Memorial Fund AMMF2020","journal-title":"Alan Morement Memorial Fund"},{"key":"ref=73","unstructured":"The Cholangiocarcinoma Foundation CCF[December 2019];","journal-title":"The Cholangiocarcinoma Foundation"},{"key":"ref=74","unstructured":"The Bili Project Foundation The Bili Project Foundation[December 2019];","journal-title":"The Bili Project Foundation"},{"key":"ref=75","unstructured":"IHPBA IHPBA[December 2019];","journal-title":"IHPBA"},{"key":"ref=76","unstructured":"ICRN ICRN[December 2019];","journal-title":"ICRN"},{"key":"ref=77","unstructured":"ENS-CCA ENS-CCA[December 2019];","journal-title":"ENS-CCA"},{"key":"ref=78","unstructured":"Making a impact in rarer cancers \u2013 the ABC02 trial Cancer Research UK [19th March 2017];2017","journal-title":"Making a impact in rarer cancers \u2013 the ABC02 trial"},{"key":"ref=79","unstructured":"Biliary tract cancer; category: rare cancer NIH (National Institute of Health) [19th March 2017]; 2017","journal-title":"Biliary tract cancer; category: rare cancer"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1349-7006.2009.01458.x","volume":"101","author":"Shin H.R.","year":"2010","unstructured":"Shin H.R.; Oh J.K.; Masuyer E.; Curado M.P.; Bouvard V.; Fang Y.Y.; Wiangnon S.; Sripa B.; Hong S.T.; Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci 2010,101(3),579-585","journal-title":"Cancer Sci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1200\/JOP.2011.000476","volume":"8","author":"Baer A.R.","year":"2012","unstructured":"Baer A.R.; Michaels M.; Good M.J.; Schapira L.; Engaging referring physicians in the clinical trial process. J Oncol Pract 2012,8(1),e8-e10","journal-title":"J Oncol Pract"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"996","DOI":"10.21037\/jgo.2016.09.10","volume":"7","author":"Agarwal R.","year":"2016","unstructured":"Agarwal R.; Sendilnathan A.; Siddiqi N.I.; Gulati S.; Ghose A.; Xie C.; Olowokure O.O.; Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States. J Gastrointest Oncol 2016,7(6),996-1003","journal-title":"J Gastrointest Oncol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"44995","DOI":"10.18632\/oncotarget.5707","volume":"6","author":"Horgan A.","year":"2015","unstructured":"Horgan A.; Knox J.; Aneja P.; Le L.; McKeever E.; McNamara M.; Patterns of care and treatment outcomes in older patients with biliary tract cancer. Oncotarget 2015,6(42),44995-45004","journal-title":"Oncotarget"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.ejca.2015.04.011","volume":"51","author":"Grunnet M.","year":"2015","unstructured":"Grunnet M.; Christensen I.J.; Lassen U.; Jensen L.H.; Lydolph M.; Knox J.J.; McNamara M.G.; Jitlal M.; Wasan H.; Bridgewater J.; Valle J.W.; Mau-Sorensen M.; Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. Eur J Cancer 2015,51(11),1381-1388","journal-title":"Eur J Cancer"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.3748\/wjg.v22.i26.6065","volume":"22","author":"Lamarca A.","year":"2016","unstructured":"Lamarca A.; Rigby C.; McNamara M.G.; Hubner R.A.; Valle J.W.; Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy. World J Gastroenterol 2016,22(26),6065-6075","journal-title":"World J Gastroenterol"},{"key":"ref=86","unstructured":"Just Diagnosed\nwith Cholangiocarcinoma? Here are some next\nsteps The Cholangiocarcinoma Foundation (CCF) [20th March 2017];","journal-title":"Just Diagnosed\nwith Cholangiocarcinoma? Here are some next\nsteps"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1745-6215-15-5","volume":"15","author":"Donovan J.L.","year":"2014","unstructured":"Donovan J.L.; Paramasivan S.; de Salis I.; Toerien M.; Clear obstacles and hidden challenges: understanding recruiter perspectives in six pragmatic randomised controlled trials. Trials 2014,15,5","journal-title":"Trials"},{"key":"ref=88","first-page":"205","volume":"53","author":"Thoma A.","year":"2010","unstructured":"Thoma A.; Farrokhyar F.; McKnight L.; Bhandari M.; Practical tips for surgical research: how to optimize patient recruitment. Can J Surg 2010,53(3),205-210","journal-title":"Can J Surg"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.2196\/jmir.6798","volume":"19","author":"Krischer J.","year":"2017","unstructured":"Krischer J.; Cronholm P.F.; Burroughs C.; McAlear C.A.; Borchin R.; Easley E.; Davis T.; Kullman J.; Carette S.; Khalidi N.; Koening C.; Langford C.A.; Monach P.; Moreland L.; Pagnoux C.; Specks U.; Sreih A.G.; Ytterberg S.; Merkel P.A.; Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. J Med Internet Res Vasculitis Clinical Research Consortium2017,19(2),e50","journal-title":"J Med Internet Res"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"e2002040","DOI":"10.1371\/journal.pbio.2002040","volume":"15","author":"Caplan A.","year":"2017","unstructured":"Caplan A.; Friesen P.; Health disparities and clinical trial recruitment: Is there a duty to tweet? PLoS Biol 2017,15(3),e2002040","journal-title":"PLoS Biol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/1097-0142(19920915)70:6<1493: AID-CNCR2820700608>3.0.CO;2-U","volume":"70","author":"Henson D.E.","year":"1992","unstructured":"Henson D.E.; Albores-Saavedra J.; Corle D.; Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer 1992,70(6),1493-1497","journal-title":"Cancer"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.amjsurg.2007.11.011","volume":"196","author":"Gourgiotis S.","year":"2008","unstructured":"Gourgiotis S.; Kocher H.M.; Solaini L.; Yarollahi A.; Tsiambas E.; Salemis N.S.; Gallbladder cancer. Am J Surg 2008,196(2),252-264","journal-title":"Am J Surg"},{"key":"ref=93","first-page":"363","volume":"14","author":"Gatto M.","year":"2010","unstructured":"Gatto M.; Alvaro D.; Cholangiocarcinoma: risk factors and clinical presentation. Eur Rev Med Pharmacol Sci 2010,14(4),363-367","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/MOG.0b013e3283378eb0","volume":"26","author":"Heinrich S.","year":"2010","unstructured":"Heinrich S.; Clavien P.A.; Ampullary cancer. Curr Opin Gastroenterol 2010,26(3),280-285","journal-title":"Curr Opin Gastroenterol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12885-016-2174-8","volume":"16","author":"Bridgewater J.","year":"2016","unstructured":"Bridgewater J.; Lopes A.; Beare S.; Duggan M.; Lee D.; Ricamara M.; McEntee D.; Sukumaran A.; Wasan H.; Valle J.W.; A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer 2016,16,153-2174","journal-title":"BMC Cancer"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1093\/annonc\/mdt191","volume":"24","author":"Jiang Z.Q.","year":"2013","unstructured":"Jiang Z.Q.; Varadhachary G.; Wang X.; Kopetz S.; Lee J.E.; Wang H.; Shroff R.; Katz M.; Wolff R.A.; Fleming J.; Overman M.J.; A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol 2013,24(9),2349-2353","journal-title":"Ann Oncol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"e65144","DOI":"10.1371\/journal.pone.0065144","volume":"8","author":"Overman M.J.","year":"2013","unstructured":"Overman M.J.; Zhang J.; Kopetz S.; Davies M.; Jiang Z.Q.; Stemke-Hale K.; R\u00fcmmele P.; Pilarsky C.; Gr\u00fctzmann R.; Hamilton S.; Hwang R.; Abbruzzese J.L.; Varadhachary G.; Broom B.; Wang H.; Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One 2013,8(6),e65144","journal-title":"PLoS One"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2008.19.7145","volume":"27","author":"Overman M.J.","year":"2009","unstructured":"Overman M.J.; Varadhachary G.R.; Kopetz S.; Adinin R.; Lin E.; Morris J.S.; Eng C.; Abbruzzese J.L.; Wolff R.A.; Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol 2009,27(16),2598-2603","journal-title":"J Clin Oncol"},{"key":"ref=99","volume":"33","author":"Jeffrey S.","year":"2015","unstructured":"Jeffrey S.; Ross, KWDVTCea. Comprehensive genomic\nprofiling of biliary tract cancers to reveal tumor-specific differences\nand genomic alterations. [ASCO Annual Meeting\n2015 J Clin Oncol 2015,33(suppl 3; abstr 231)","journal-title":"J Clin Oncol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1471-2407-11-60","volume":"11","author":"Deshpande V.","year":"2011","unstructured":"Deshpande V.; Nduaguba A.; Zimmerman S.M.; Kehoe S.M.; Macconaill L.E.; Lauwers G.Y.; Ferrone C.; Bardeesy N.; Zhu A.X.; Hezel A.F.; Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer 2011,11,60","journal-title":"BMC Cancer"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","volume":"17","author":"Borger D.R.","year":"2012","unstructured":"Borger D.R.; Tanabe K.K.; Fan K.C.; Lopez H.U.; Fantin V.R.; Straley K.S.; Schenkein D.P.; Hezel A.F.; Ancukiewicz M.; Liebman H.M.; Kwak E.L.; Clark J.W.; Ryan D.P.; Deshpande V.; Dias-Santagata D.; Ellisen L.W.; Zhu A.X.; Iafrate A.J.; Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012,17(1),72-79","journal-title":"Oncologist"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","volume":"36","author":"Galdy S.","year":"2017","unstructured":"Galdy S.; Lamarca A.; McNamara M.G.; Hubner R.A.; Cella C.A.; Fazio N.; Valle J.W.; HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev 2017,36(1),141-157","journal-title":"Cancer Metastasis Rev"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/gcc.20540","volume":"47","author":"Riener M.O.","year":"2008","unstructured":"Riener M.O.; Bawohl M.; Clavien P.A.; Jochum W.; Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer 2008,47(5),363-367","journal-title":"Genes Chromosomes Cancer"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/ng.3030","volume":"46","author":"Li M.","year":"2014","unstructured":"Li M.; Zhang Z.; Li X.; Ye J.; Wu X.; Tan Z.; Liu C.; Shen B.; Wang X.A.; Wu W.; Zhou D.; Zhang D.; Wang T.; Liu B.; Qu K.; Ding Q.; Weng H.; Ding Q.; Mu J.; Shu Y.; Bao R.; Cao Y.; Chen P.; Liu T.; Jiang L.; Hu Y.; Dong P.; Gu J.; Lu W.; Shi W.; Lu J.; Gong W.; Tang Z.; Zhang Y.; Wang X.; Chin Y.E.; Weng X.; Zhang H.; Tang W.; Zheng Y.; He L.; Wang H.; Liu Y.; Liu Y.; Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet 2014,46(8),872-876","journal-title":"Nat Genet"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/PAI.0b013e3181f09179","volume":"19","author":"Pai R.K.","year":"2011","unstructured":"Pai R.K.; Mojtahed K.; Pai R.K.; Mutations in the RAS\/RAF\/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas. Appl Immunohistochem Mol Morphol 2011,19(2),133-140","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","volume":"19","author":"Ross J.S.","year":"2014","unstructured":"Ross J.S.; Wang K.; Gay L.; Al-Rohil R.; Rand J.V.; Jones D.M.; Lee H.J.; Sheehan C.E.; Otto G.A.; Palmer G.; Yelensky R.; Lipson D.; Morosini D.; Hawryluk M.; Catenacci D.V.; Miller V.A.; Churi C.; Ali S.; Stephens P.J.; New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 2014,19(3),235-242","journal-title":"Oncologist"},{"key":"ref=107","volume":"33","author":"Randall F.","year":"2015","unstructured":"Randall F.; Tumor profiling of biliary\ntract carcinomas to reveal distinct molecular alterations and\npotential therapeutic targets. [ASCO Annual Meeting J Clin\nOncol Holcombe, JXMJPea2015,33(suppl 3; abstr 285)","journal-title":"J Clin\nOncol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/hep.26890","volume":"59","author":"Arai Y.","year":"2014","unstructured":"Arai Y.; Totoki Y.; Hosoda F.; Shirota T.; Hama N.; Nakamura H.; Ojima H.; Furuta K.; Shimada K.; Okusaka T.; Kosuge T.; Shibata T.; Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 2014,59(4),1427-1434","journal-title":"Hepatology"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"6087","DOI":"10.1038\/ncomms7087","volume":"6","author":"Sia D.","year":"2015","unstructured":"Sia D.; Losic B.; Moeini A.; Cabellos L.; Hao K.; Revill K.; Bonal D.; Miltiadous O.; Zhang Z.; Hoshida Y.; Cornella H.; Castillo-Martin M.; Pinyol R.; Kasai Y.; Roayaie S.; Thung S.N.; Fuster J.; Schwartz M.E.; Waxman S.; Cordon-Cardo C.; Schadt E.; Mazzaferro V.; Llovet J.M.; Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun 2015,6,6087","journal-title":"Nat Commun"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","volume":"9","author":"Churi C.R.","year":"2014","unstructured":"Churi C.R.; Shroff R.; Wang Y.; Rashid A.; Kang H.C.; Weatherly J.; Zuo M.; Zinner R.; Hong D.; Meric-Bernstam F.; Janku F.; Crane C.H.; Mishra L.; Vauthey J.N.; Wolff R.A.; Mills G.; Javle M.; Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 2014,9(12),e115383","journal-title":"PLoS One"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","volume":"45","author":"Graham R.P.","year":"2014","unstructured":"Graham R.P.; Barr Fritcher E.G.; Pestova E.; Schulz J.; Sitailo L.A.; Vasmatzis G.; Murphy S.J.; McWilliams R.R.; Hart S.N.; Halling K.C.; Roberts L.R.; Gores G.J.; Couch F.J.; Zhang L.; Borad M.J.; Kipp B.R.; Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol 2014,45(8),1630-1638","journal-title":"Hum Pathol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"Turner N.","year":"2010","unstructured":"Turner N.; Grose R.; Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010,10(2),116-129","journal-title":"Nat Rev Cancer"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/ng.2806","volume":"45","author":"Chan-On W.","year":"2013","unstructured":"Chan-On W.; Nairism\u00e4gi M.L.; Ong C.K.; Lim W.K.; Dima S.; Pairojkul C.; Lim K.H.; McPherson J.R.; Cutcutache I.; Heng H.L.; Ooi L.; Chung A.; Chow P.; Cheow P.C.; Lee S.Y.; Choo S.P.; Tan I.B.; Duda D.; Nastase A.; Myint S.S.; Wong B.H.; Gan A.; Rajasegaran V.; Ng C.C.; Nagarajan S.; Jusakul A.; Zhang S.; Vohra P.; Yu W.; Huang D.; Sithithaworn P.; Yongvanit P.; Wongkham S.; Khuntikeo N.; Bhudhisawasdi V.; Popescu I.; Rozen S.G.; Tan P.; Teh B.T.; Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet 2013,45(12),1474-1478","journal-title":"Nat Genet"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/modpathol.2015.57","volume":"28","author":"Hechtman J.F.","year":"2015","unstructured":"Hechtman J.F.; Liu W.; Sadowska J.; Zhen L.; Borsu L.; Arcila M.E.; Won H.H.; Shah R.H.; Berger M.F.; Vakiani E.; Shia J.; Klimstra D.S.; Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). Mod Pathol 2015,28(8),1123-1129","journal-title":"Mod Pathol"},{"key":"ref=115","author":"Mafficini A.","year":"2016","unstructured":"Mafficini A.; Amato E.; Cataldo I.; Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations. Ann Surg 2016","journal-title":"Ann Surg"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.prp.2017.01.004","volume":"213","author":"Kwon M.J.","year":"2017","unstructured":"Kwon M.J.; Kim J.W.; Jeon J.Y.; Nam E.S.; Cho S.J.; Park H.R.; Min S.K.; Seo J.; Min K.W.; Choe J.Y.; Lee H.K.; Concurrent MET copy number gain and KRAS mutation is a poor prognostic factor in pancreatobiliary subtype ampullary cancers. Pathol Res Pract 2017,213(4),381-388","journal-title":"Pathol Res Pract"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1148\/rg.296095514","volume":"29","author":"Yeh B.M.","year":"2009","unstructured":"Yeh B.M.; Liu P.S.F.A.; Soto J.A.F.A.; Corvera C.A.; Hussain H.K.; MR imaging and CT of the biliary tract. Radiographics 2009,29(6),1669-1688","journal-title":"Radiographics"},{"key":"ref=118","author":"Mittal P.K.","year":"2014","unstructured":"Mittal P.K.; Moreno C.C.F.A.; Kalb, B.F.A.U. - Primary biliary tract malignancies: MRI spectrum and mimics with histopathological correlation. -. Abdom Imaging 2014","journal-title":"Abdom Imaging"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-2001-11667","volume":"33","author":"Sch\u00f6fl R.","year":"2001","unstructured":"Sch\u00f6fl R.; Diagnostic endoscopic retrograde cholangiopancreatography. Endoscopy 2001,33(2),147-157","journal-title":"Endoscopy"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"Eisenhauer E.A.","year":"2009","unstructured":"Eisenhauer E.A.; Therasse P.; Bogaerts J.; Schwartz L.H.; Sargent D.; Ford R.; Dancey J.; Arbuck S.; Gwyther S.; Mooney M.; Rubinstein L.; Shankar L.; Dodd L.; Kaplan R.; Lacombe D.; Verweij J.; New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009,45(2),228-247","journal-title":"Eur J Cancer"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1159\/000439097","volume":"33","author":"Piscaglia F.","year":"2015","unstructured":"Piscaglia F.; Iavarone M.; Galassi M.; Vavassori S.; Renzulli M.; Forzenigo L.V.; Granito A.; Salvatore V.; Sangiovanni A.; Golfieri R.; Colombo M.; Bolondi L.; Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging. Dig Dis 2015,33(6),735-744","journal-title":"Dig Dis"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"222","DOI":"10.5152\/dir.2014.13184","volume":"20","author":"Galia M.","year":"2014","unstructured":"Galia M.; Taibbi A.; Marin D.; Furlan A.; Dioguardi Burgio M.; Agnello F.; Cabibbo G.; Van Beers B.E.; Bartolotta T.V.; Midiri M.; Lagalla R.; Brancatelli G.; Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma? Diagn Interv Radiol 2014,20(3),222-228","journal-title":"Diagn Interv Radiol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.hpb.2016.07.006","volume":"18","author":"Bergquist J.R.","year":"2016","unstructured":"Bergquist J.R.; Groeschl R.T.; Ivanics T.; Shubert C.R.; Habermann E.B.; Kendrick M.L.; Farnell M.B.; Nagorney D.M.; Truty M.J.; Smoot R.L.; Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics. HPB (Oxford) 2016,18(11),886-892","journal-title":"HPB (Oxford)"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jhep.2017.01.010","volume":"66","author":"Moeini A.","year":"2017","unstructured":"Moeini A.; Sia D.; Zhang Z.; Camprecios G.; Stueck A.; Dong H.; Montal R.; Torrens L.; Martinez-Quetglas I.; Fiel M.I.; Hao K.; Villanueva A.; Thung S.N.; Schwartz M.E.; Llovet J.M.; Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol 2017,66(5),952-961","journal-title":"J Hepatol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"e0154985","DOI":"10.1371\/journal.pone.0154985","volume":"11","author":"Raghav K.","year":"2016","unstructured":"Raghav K.; Mhadgut H.; McQuade J.L.; Lei X.; Ross A.; Matamoros A.; Wang H.; Overman M.J.; Varadhachary G.R.; Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes. PLoS One 2016,11(5),e0154985","journal-title":"PLoS One"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/dc.23096","volume":"42","author":"Brugge W.","year":"2014","unstructured":"Brugge W.; Dewitt J.; Klapman J.B.F.A.; Ashfaq R.; Shidham V.; Chhieng D.; Kwon R.; Baloch Z.; Zarka M.; Staerkel G.; Papanicolaou Society of Cytopathology. Techniques for cytologic sampling of pancreatic and bile duct lesions. Diagn Cytopathol 2014,42(4),333-337","journal-title":"Diagn Cytopathol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/j.cgh.2009.08.027","volume":"7","author":"Inui K.","year":"2009","unstructured":"Inui K.; Yoshino J.; Miyoshi H.; Differential diagnosis and treatment of biliary strictures. Clin Gastroenterol Hepatol 2009,7(11)(Suppl.),S79-S83","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1097\/01.smj.0000251324.81191.cd","volume":"99","author":"Brugge W.R.","year":"2006","unstructured":"Brugge W.R.; Advances in the endoscopic management of patients with pancreatic and biliary malignancies. South Med J 2006,99(12),1358-1366","journal-title":"South Med J"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"420","DOI":"10.4251\/wjgo.v6.i11.420","volume":"6","author":"Hammoud G.M.","year":"2014","unstructured":"Hammoud G.M.; Almashhrawi A.; Ibdah J.A.; Usefulness of endoscopic ultrasound-guided fine needle aspiration in the diagnosis of hepatic, gallbladder and biliary tract Lesions. World J Gastrointest Oncol 2014,6(11),420-429","journal-title":"World J Gastrointest Oncol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4103\/2303-9027.123011","volume":"3","author":"Fuccio L.","year":"2014","unstructured":"Fuccio L.; Larghi A.; Endoscopic ultrasound-guided fine needle aspiration: How to obtain a core biopsy? Endosc Ultrasound 2014,3(2),71-81","journal-title":"Endosc Ultrasound"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/cyt.12296","volume":"27","author":"Rana C.","year":"2016","unstructured":"Rana C.; Krishnani N.; Kumari N.; Ultrasound-guided fine needle aspiration cytology of gallbladder lesions: a study of 596 cases. Cytopathology 2016,27(6),398-406","journal-title":"Cytopathology"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.gassur.2003.10.003","volume":"8","author":"Anderson C.D.","year":"2004","unstructured":"Anderson C.D.; Rice M.H.; Pinson C.W.; Chapman W.C.; Chari R.S.; Delbeke D.; Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004,8(1),90-97","journal-title":"J Gastrointest Surg"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/j.1572-0241.2007.01710.x","volume":"103","author":"Kim J.Y.","year":"2008","unstructured":"Kim J.Y.; Kim M.H.F.A.; Lee T.Y.F.A.; Hwang C.Y.; Kim J.S.; Yun S.C.; Lee S.S.; Seo D.W.; Lee S.K.; Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol 2008,103(5),1145-1151","journal-title":"Am J Gastroenterol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3390\/cancers6041821","volume":"6","author":"Gallamini A.","year":"2014","unstructured":"Gallamini A.; Zwarthoed C.; Borra A.; Positron Emission Tomography (PET) in Oncology. Cancers (Basel) 2014,6(4),1821-1889","journal-title":"Cancers (Basel)"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/01.rct.0000237811.88251.d7","volume":"31","author":"Jadvar H.","year":"2007","unstructured":"Jadvar H.; Henderson R.W.; Conti P.S.; [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma. J Comput Assist Tomogr 2007,31(2),223-228","journal-title":"J Comput Assist Tomogr"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jhep.2006.03.009","volume":"45","author":"Petrowsky H.","year":"2006","unstructured":"Petrowsky H.; Wildbrett P.; Husarik D.B.; Hany T.F.; Tam S.; Jochum W.; Clavien P.A.; Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006,45(1),43-50","journal-title":"J Hepatol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1477-2574.2008.00009.x","volume":"11","author":"Garcea G.","year":"2009","unstructured":"Garcea G.; Ong S.L.; Maddern G.J.; The current role of PET-CT in the characterization of hepatobiliary malignancies. HPB (Oxford) 2009,11(1),4-17","journal-title":"HPB (Oxford)"},{"key":"ref=138","year":"2013","unstructured":"Evidence-based indications for the use of PETCT\nin the UK 2013 London: RCP, RCP, 2013 The Royal College of Physicians and The Royal College of RadiologistRef Type: Abstract2013","journal-title":"Evidence-based indications for the use of PETCT\nin the UK 2013 London: RCP, RCP, 2013"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"W260-5","DOI":"10.2214\/AJR.11.6995","volume":"197","author":"Sacks A.","year":"2011","unstructured":"Sacks A.; Peller P.J.; Surasi D.S.; Chatburn L.; Mercier G.; Subramaniam R.M.; Value of PET\/CT in the management of primary hepatobiliary tumors, part 2. AJR Am J Roentgenol 2011,197(2),W260-5","journal-title":"AJR Am J Roentgenol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jhep.2019.01.038","volume":"71","author":"Lamarca A.","year":"2019","unstructured":"Lamarca A.; Barriuso J.; Chander A.; McNamara M.G.; Hubner R.A.; \u00d3Reilly D.; Manoharan P.; Valle J.W.; 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. J Hepatol 2019,71(1),115-129","journal-title":"J Hepatol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","year":"2001","unstructured":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther Biomarkers Definitions Working Group2001,69(3),89-95","journal-title":"Clin Pharmacol Ther"},{"key":"ref=142","first-page":"1030","volume":"20","author":"Natsios A.","year":"2015","unstructured":"Natsios A.; Vezakis A.; Kaparos G.; Fragulidis G.; Karakostas N.; Kouskouni E.; Logothetis E.; Polydorou A.; Significance of serum and bile tumor markers in the diagnostic approach of patients with malignant pancreatobiliary disease. J BUON 2015,20(4),1030-1036","journal-title":"J BUON"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4143\/crt.2016.326","volume":"49","author":"Lee D.W.","year":"2017","unstructured":"Lee D.W.; Im, S.A.; Kim, Y.J.; Yang, Y.; Rhee, J.; Na, I.I.; Lee, K.H.; Kim, T.Y.; Han, S.W.; Choi, I.S.; Oh, D.Y.; Kim, J.H.; Kim, T.Y.; Bang, Y.J. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy. Cancer Res Treat 2017,49(3),807-815","journal-title":"Cancer Res Treat"},{"key":"ref=144","first-page":"744","volume":"7","author":"Lin M.S.","year":"2014","unstructured":"Lin M.S.; Huang J.X.; Yu H.; Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker. Int J Clin Exp Med 2014,7(3),744-750","journal-title":"Int J Clin Exp Med"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/978-94-017-7215-0_15","volume":"867","author":"Scar\u00e0 S.","year":"2015","unstructured":"Scar\u00e0 S.; Bottoni P.; Scatena R.; CA 19-9: Biochemical and Clinical Aspects. Adv Exp Med Biol 2015,867,247-260","journal-title":"Adv Exp Med Biol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1136\/jclinpath-2015-203418","volume":"69","author":"Bertram S.","year":"2016","unstructured":"Bertram S.; Padden J.; K\u00e4lsch J.; Ahrens M.; Pott L.; Canbay A.; Weber F.; Fingas C.; Hoffmann A.C.; Vietor A.; Schlaak J.F.; Eisenacher M.; Reis H.; Sitek B.; Baba H.A.; Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions. J Clin Pathol 2016,69(7),619-626","journal-title":"J Clin Pathol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/den.12823","volume":"29","author":"Bhatia V.","year":"2017","unstructured":"Bhatia V.; Varadarajulu S.; Endoscopic ultrasonography-guided tissue acquisition: How to achieve excellence. Dig Endosc 2017,29(4),417-430","journal-title":"Dig Endosc"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1245\/s10434-013-3286-x","volume":"21","author":"Ruys A.T.","year":"2014","unstructured":"Ruys A.T.; Groot Koerkamp B.; Wiggers J.K.; Kl\u00fcmpen H.J.; ten Kate F.J.; van Gulik T.M.; Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol 2014,21(2),487-500","journal-title":"Ann Surg Oncol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1158\/1078-0432.CCR-14-3296","volume":"22","author":"Moeini A.","year":"2016","unstructured":"Moeini A.; Sia D.; Bardeesy N.; Mazzaferro V.; Llovet J.M.; Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. Clin Cancer Res 2016,22(2),291-300","journal-title":"Clin Cancer Res"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2217\/fon.12.20","volume":"8","author":"Argiles G.","year":"2012","unstructured":"Argiles G.; Dienstmann R.; Elez E.; Tabernero J.; Panitumumab: a summary of clinical development in colorectal cancer and future directions. Future Oncol 2012,8(4),373-389","journal-title":"Future Oncol"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"Amado R.G.","year":"2008","unstructured":"Amado R.G.; Wolf M.; Peeters M.; Van Cutsem E.; Siena S.; Freeman D.J.; Juan T.; Sikorski R.; Suggs S.; Radinsky R.; Patterson S.D.; Chang D.D.; Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008,26(10),1626-1634","journal-title":"J Clin Oncol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"Douillard J.Y.","year":"2013","unstructured":"Douillard J.Y.; Oliner K.S.; Siena S.; Tabernero J.; Burkes R.; Barugel M.; Humblet Y.; Bodoky G.; Cunningham D.; Jassem J.; Rivera F.; Koc\u00e1kova I.; Ruff P.; B\u0142asi\u0144ska-Morawiec M.; \u0160makal M.; Canon J.L.; Rother M.; Williams R.; Rong A.; Wiezorek J.; Sidhu R.; Patterson S.D.; Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013,369(11),1023-1034","journal-title":"N Engl J Med"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1158\/2159-8290.CD-15-0274","volume":"5","author":"Zill O.A.","year":"2015","unstructured":"Zill O.A.; Greene C.; Sebisanovic D.; Siew L.M.; Leng J.; Vu M.; Hendifar A.E.; Wang Z.; Atreya C.E.; Kelley R.K.; Van Loon K.; Ko A.H.; Tempero M.A.; Bivona T.G.; Munster P.N.; Talasaz A.; Collisson E.A.; Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov 2015,5(10),1040-1048","journal-title":"Cancer Discov"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"E791","DOI":"10.3390\/ijms17050791","volume":"17","author":"Letelier P.","year":"2016","unstructured":"Letelier P.; Riquelme I.; Hern\u00e1ndez A.H.; Guzm\u00e1n N.; Far\u00edas J.G.; Roa J.C.; Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers. Int J Mol Sci 2016,17(5),E791","journal-title":"Int J Mol Sci"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(08)70027-5","volume":"9","author":"Bonney G.K.","year":"2008","unstructured":"Bonney G.K.; Craven R.A.; Prasad R.; Melcher A.F.; Selby P.J.; Banks R.E.; Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol 2008,9(2),149-158","journal-title":"Lancet Oncol"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","volume":"7","author":"Goyal L.","year":"2017","unstructured":"Goyal L.; Saha S.K.; Liu L.Y.; Siravegna G.; Leshchiner I.; Ahronian L.G.; Lennerz J.K.; Vu P.; Deshpande V.; Kambadakone A.; Mussolin B.; Reyes S.; Henderson L.; Sun J.E.; Van Seventer E.E.; Gurski J.M.; Baltschukat S.; Schacher-Engstler B.; Barys L.; Stamm C.; Furet P.; Ryan D.P.; Stone J.R.; Iafrate A.J.; Getz G.; Porta D.G.; Tiedt R.; Bardelli A.; Juric D.; Corcoran R.B.; Bardeesy N.; Zhu A.X.; Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov 2017,7(3),252-263","journal-title":"Cancer Discov"},{"key":"ref=157","unstructured":"ATCC ATCC[March 2017];","journal-title":"ATCC"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"83060","DOI":"10.18632\/oncotarget.13067","volume":"7","author":"Li M.","year":"2016","unstructured":"Li M.; Chen W.; Zhang H.; Zhang Y.; Ke F.; Wu X.; Zhang Y.; Weng M.; Liu Y.; Gong W.; MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer. Oncotarget 2016,7(50),83060-83070","journal-title":"Oncotarget"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00428-003-0936-6","volume":"444","author":"Sorio C.","year":"2004","unstructured":"Sorio C.; Moore P.S.; Ennas M.G.; Tecchio C.; Bonora A.; Sartoris S.; Balzarini P.; Grigolato P.; Scarpa A.; A novel cell line and xenograft model of ampulla of Vater adenocarcinoma. Virchows Arch 2004,444(3),269-277","journal-title":"Virchows Arch"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"58007","DOI":"10.18632\/oncotarget.11157","volume":"7","author":"Nam A.R.","year":"2016","unstructured":"Nam A.R.; Kim J.W.; Cha Y.; Ha H.; Park J.E.; Bang J.H.; Jin M.H.; Lee K.H.; Kim T.Y.; Han S.W.; Im, S.A.; Kim, T.Y.; Oh, D.Y.; Bang, Y.J. Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget 2016,7(36),58007-58021","journal-title":"Oncotarget"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"36319","DOI":"10.18632\/oncotarget.16751","volume":"8","author":"Li M.","year":"2017","unstructured":"Li M.; Chen L.; Qu Y.; Sui F.; Yang Q.; Ji M.; Shi B.; Chen M.; Hou P.; Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing. Oncotarget 2017,8(22),36319-36330","journal-title":"Oncotarget"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.canlet.2016.05.017","volume":"380","author":"Wang Y.","year":"2016","unstructured":"Wang Y.; Ding X.; Wang S.; Moser C.D.; Shaleh H.M.; Mohamed E.A.; Chaiteerakij R.; Allotey L.K.; Chen G.; Miyabe K.; McNulty M.S.; Ndzengue A.; Barr Fritcher E.G.; Knudson R.A.; Greipp P.T.; Clark K.J.; Torbenson M.S.; Kipp B.R.; Zhou J.; Barrett M.T.; Gustafson M.P.; Alberts S.R.; Borad M.J.; Roberts L.R.; Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. Cancer Lett 2016,380(1),163-173","journal-title":"Cancer Lett"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"17220","DOI":"10.18632\/oncotarget.7948","volume":"7","author":"Peng H.","year":"2016","unstructured":"Peng H.; Zhang Q.; Li J.; Zhang N.; Hua Y.; Xu L.; Deng Y.; Lai J.; Peng Z.; Peng B.; Chen M.; Peng S.; Kuang M.; Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget 2016,7(13),17220-17229","journal-title":"Oncotarget"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1159\/000475454","volume":"41","author":"Liang H.B.","year":"2017","unstructured":"Liang H.B.; Cao Y.; Ma Q.; Shu Y.J.; Wang Z.; Zhang F.; Ye Y.Y.; Li H.F.; Xiang S.S.; Song X.L.; Xu Y.; Zhang Y.C.; Bao R.F.; Yuan R.Y.; Zhang Y.J.; Hu Y.P.; Jiang L.; Li M.L.; Wang X.A.; Wu X.S.; Wu W.G.; Zhao S.; Fand Y.; Cui X.P.; Lu Y.S.; Zhou J.; Zheng L.; Gong W.; Liu Y.B.; MYBL2 is a Potential Prognostic Marker that Promotes Cell Proliferation in Gallbladder Cancer. Cell Physiol Biochem 2017,41(5),2117-2131","journal-title":"Cell Physiol Biochem"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13046-016-0370-7","volume":"35","author":"Zhao S.","year":"2016","unstructured":"Zhao S.; Cao Y.; Liu S.B.; Wang X.A.; Bao R.F.; Shu Y.J.; Hu Y.P.; Zhang Y.J.; Jiang L.; Zhang F.; Liang H.B.; Li H.F.; Ma Q.; Xu Y.; Wang Z.; Zhang Y.C.; Chen L.; Zhou J.; Liu Y.B.; The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR. J Exp Clin Cancer Res 2016,35(1),97-0370","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ccr.2013.04.019","volume":"23","author":"Zender S.","year":"2013","unstructured":"Zender S.; Nickeleit I.; Wuestefeld T.; S\u00f6rensen I.; Dauch D.; Bozko P.; El-Khatib M.; Geffers R.; Bektas H.; Manns M.P.; Gossler A.; Wilkens L.; Plentz R.; Zender L.; Malek N.P.; A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell 2013,23(6),784-795","journal-title":"Cancer Cell"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature13441","volume":"513","author":"Saha S.K.","year":"2014","unstructured":"Saha S.K.; Parachoniak C.A.; Ghanta K.S.; Fitamant J.; Ross K.N.; Najem M.S.; Gurumurthy S.; Akbay E.A.; Sia D.; Cornella H.; Miltiadous O.; Walesky C.; Deshpande V.; Zhu A.X.; Hezel A.F.; Yen K.E.; Straley K.S.; Travins J.; Popovici-Muller J.; Gliser C.; Ferrone C.R.; Apte U.; Llovet J.M.; Wong K.K.; Ramaswamy S.; Bardeesy N.; Mutant IDH inhibits HNF-4\u03b1 to block hepatocyte differentiation and promote biliary cancer. Nature 2014,513(7516),110-114","journal-title":"Nature"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1101\/gad.226302","volume":"16","author":"Kalamarides M.","year":"2002","unstructured":"Kalamarides M.; Niwa-Kawakita M.; Leblois H.; Abramowski V.; Perricaudet M.; Janin A.; Thomas G.; Gutmann D.H.; Giovannini M.; Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 2002,16(9),1060-1065","journal-title":"Genes Dev"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1172\/JCI27282","volume":"116","author":"Xu X.","year":"2006","unstructured":"Xu X.; Kobayashi S.; Qiao W.; Li C.; Xiao C.; Radaeva S.; Stiles B.; Wang R.H.; Ohara N.; Yoshino T.; LeRoith D.; Torbenson M.S.; Gores G.J.; Wu H.; Gao B.; Deng C.X.; Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 2006,116(7),1843-1852","journal-title":"J Clin Invest"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/MOG.0b013e32835d6a3e","volume":"29","author":"Ko K.S.","year":"2013","unstructured":"Ko K.S.; Peng J.; Yang H.; Animal models of cholangiocarcinoma. Curr Opin Gastroenterol 2013,29(3),312-318","journal-title":"Curr Opin Gastroenterol"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1002\/hep.25914","volume":"56","author":"Liu W.","year":"2012","unstructured":"Liu W.; Chen J.R.; Hsu C.H.; Li Y.H.; Chen Y.M.; Lin C.Y.; Huang S.J.; Chang Z.K.; Chen Y.C.; Lin C.H.; Gong H.Y.; Lin C.C.; Kawakami K.; Wu J.L.; A zebrafish model of intrahepatic cholangiocarcinoma by dual expression of hepatitis B virus X and hepatitis C virus core protein in liver. Hepatology 2012,56(6),2268-2276","journal-title":"Hepatology"},{"key":"ref=172","first-page":"6971","volume":"61","author":"Kiguchi K.","year":"2001","unstructured":"Kiguchi K.; Carbajal S.; Chan K.; Beltr\u00e1n L.; Ruffino L.; Shen J.; Matsumoto T.; Yoshimi N.; DiGiovanni J.; Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 2001,61(19),6971-6976","journal-title":"Cancer Res"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","volume":"160","author":"Boj S.F.","year":"2015","unstructured":"Boj S.F.; Hwang C.I.; Baker L.A.; Chio I.I.; Engle D.D.; Corbo V.; Jager M.; Ponz-Sarvise M.; Tiriac H.; Spector M.S.; Gracanin A.; Oni T.; Yu K.H.; van Boxtel R.; Huch M.; Rivera K.D.; Wilson J.P.; Feigin M.E.; \u00d6hlund D.; Handly-Santana A.; Ardito-Abraham C.M.; Ludwig M.; Elyada E.; Alagesan B.; Biffi G.; Yordanov G.N.; Delcuze B.; Creighton B.; Wright K.; Park Y.; Morsink F.H.; Molenaar I.Q.; Borel Rinkes I.H.; Cuppen E.; Hao Y.; Jin Y.; Nijman I.J.; Iacobuzio-Donahue C.; Leach S.D.; Pappin D.J.; Hammell M.; Klimstra D.S.; Basturk O.; Hruban R.H.; Offerhaus G.J.; Vries R.G.; Clevers H.; Tuveson D.A.; Organoid models of human and mouse ductal pancreatic cancer. Cell 2015,160(1-2),324-338","journal-title":"Cell"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/bjc.2016.64","volume":"114","author":"Bridgewater J.","year":"2016","unstructured":"Bridgewater J.; Lopes A.; Palmer D.; Cunningham D.; Anthoney A.; Maraveyas A.; Madhusudan S.; Iveson T.; Valle J.; Wasan H.; Quality of life, long-term survivors and long-term outcome from the ABC-02 study. Br J Cancer 2016,114(9),965-971","journal-title":"Br J Cancer"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/S0959-8049(02)00125-9","volume":"38","author":"Bottomley A.","year":"2002","unstructured":"Bottomley A.; Vachalec S.; Bjordal K.; Blazeby J.; Flechtner H.; Ruyskart P.; The development and utilisation of the European Organisation for research and treatment of cancer quality of life group item bank. Eur J Cancer 2002,38(12),1611-1614","journal-title":"Eur J Cancer"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"Aaronson N.K.","year":"1993","unstructured":"Aaronson N.K.; Ahmedzai S.; Bergman B.; Bullinger M.; Cull A.; Duez N.J.; Filiberti A.; Flechtner H.; Fleishman S.B.; de Haes J.C.; The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993,85(5),365-376","journal-title":"J Natl Cancer Inst"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s11136-012-0217-4","volume":"22","author":"Cella D.","year":"2013","unstructured":"Cella D.; Butt Z.; Kindler H.L.; Fuchs C.S.; Bray S.; Barlev A.; Oglesby A.; Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer. Qual Life Res 2013,22(5),1105-1112","journal-title":"Qual Life Res"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0959-8049(99)00047-7","volume":"35","author":"Fitzsimmons D.","year":"1999","unstructured":"Fitzsimmons D.; Johnson C.D.; George S.; Payne S.; Sandberg A.A.; Bassi C.; Beger H.G.; Birk D.; B\u00fcchler M.W.; Dervenis C.; Fernandez Cruz L.; Friess H.; Grahm A.L.; Jeekel J.; Laugier R.; Meyer D.; Singer M.W.; Tihanyi T.; EORTC Study Group on Quality of Life. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. Eur J Cancer 1999,35(6),939-941","journal-title":"Eur J Cancer"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1002\/cncr.27588","volume":"118","author":"Butt Z.","year":"2012","unstructured":"Butt Z.; Parikh N.D.; Beaumont J.L.; Rosenbloom S.K.; Syrjala K.L.; Abernethy A.P.; Benson A.B.; Cella D.; Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI). Cancer 2012,118(23),5997-6004","journal-title":"Cancer"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/sj.bjc.6606086","volume":"104","author":"Friend E.","year":"2011","unstructured":"Friend E.; Yadegarfar G.; Byrne C.; Johnson C.D.; Sezer O.; Pucciarelli S.; Pereira S.P.; Chie W.C.; Banfield A.; Ramage J.K.; Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21. Br J Cancer EORTC Quality of Life Group2011,104(4),587-592","journal-title":"Br J Cancer"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/bjc.2016.284","volume":"115","author":"Kaupp-Roberts S.D.","year":"2016","unstructured":"Kaupp-Roberts S.D.; Yadegarfar G.; Friend E.; O\u2019Donnell C.M.; Valle J.W.; Byrne C.; Bahar I.; Finch-Jones M.; Gillmore R.; Johnson C.D.; Pereira S.P.; Wiggers J.K.; Pinto M.; Al-Sarireh B.; Ramage J.K.; Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder. Br J Cancer 2016,115(9),1032-1038","journal-title":"Br J Cancer"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/178534","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/178534\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/178534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T11:56:52Z","timestamp":1608206212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/178534\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":181,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2020,9,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867327666200123090153","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}